Jos A G Agndez

List of Publications by Year in Descending Order

286 papers	8,491 citations	48 h-index	76 g-index
308 ext. papers	9,686 ext. citations	4.7 avg, IF	5.91 L-index

#	Paper	IF	Citations
286	Association of Essential Tremor With Novel Risk Loci: A Genome-Wide Association Study and Meta-analysis.. *JAMA Neurology*, **2022**,	17.2	3
285	Increased serum diamine oxidase activity in non-allergic patients with migraine.. *European Journal of Clinical Investigation*, **2022**, e13757	4.6	0
284	Vitamin D Receptor and Binding Protein Gene Variants in Patients with Essential Tremor.. *Molecular Neurobiology*, **2022**, 1	6.2	
283	Common UGT1A6 Variant Alleles Determine Acetaminophen Pharmacokinetics in Man. *Journal of Personalized Medicine*, **2022**, 12, 720	3.6	0
282	Sleep Disorders in Patients with Essential Tremor. *Current Neurology and Neuroscience Reports*, **2021**, 21, 23	6.6	3
281	Association between restless legs syndrome and peripheral neuropathy: A systematic review and meta-analysis. *European Journal of Neurology*, **2021**, 28, 2423-2442	6	2
280	Genetic Variants in Cytosolic Phospholipase A2 Associated With Nonsteroidal Anti-Inflammatory Drug-Induced Acute Urticaria/Angioedema. *Frontiers in Pharmacology*, **2021**, 12, 667824	5.6	1
279	Genomic Markers for Essential Tremor. *Pharmaceuticals*, **2021**, 14,	5.2	3
278	Impact of gastrointestinal tract variability on oral drug absorption and pharmacokinetics: An UNGAP review. *European Journal of Pharmaceutical Sciences*, **2021**, 162, 105812	5.1	41
277	PharmVar GeneFocus: CYP2C19. *Clinical Pharmacology and Therapeutics*, **2021**, 109, 352-366	6.1	27
276	ARADyAL: The Spanish Multidisciplinary Research Network for Allergic Diseases. *Journal of Investigational Allergology and Clinical Immunology*, **2021**, 31, 108-119	2.3	2
275	Cerebrospinal and blood levels of amino acids as potential biomarkers for Parkinson's disease: review and meta-analysis. Response to letter to the editor by Zheng et al. *European Journal of Neurology*, **2021**, 28, e13-e14	6	0
274	Serum vitamin D, vitamin D receptor and binding protein genes polymorphisms in restless legs syndrome. *Journal of Neurology*, **2021**, 268, 1461-1472	5.5	1
273	Exome-wide rare variant analysis in familial essential tremor. *Parkinsonism and Related Disorders*, **2021**, 82, 109-116	3.6	5
272	Biological fluid levels of iron and iron-related proteins in Parkinson's disease: Review and meta-analysis. *European Journal of Neurology*, **2021**, 28, 1041-1055	6	3
271	Common Endothelial Nitric Oxide Synthase Single Nucleotide Polymorphisms are not Related With the Risk for Restless Legs Syndrome. *Frontiers in Pharmacology*, **2021**, 12, 618989	5.6	0
270	Variability of the Genes Involved in the Cellular Redox Status and Their Implication in Drug Hypersensitivity Reactions. *Antioxidants*, **2021**, 10,	7.1	1

269	Deep sequencing of prostaglandin-endoperoxide synthase (PTGE) genes reveals genetic susceptibility for cross-reactive hypersensitivity to NSAID. *British Journal of Pharmacology*, **2021**, 178, 1218-1233	8.6	2
268	PharmVar GeneFocus: CYP2C9. *Clinical Pharmacology and Therapeutics*, **2021**, 110, 662-676	6.1	7
267	Lack of Major Involvement of Common Gene Polymorphisms in the Risk of Developing Cross-Hypersensitivity to NSAIDs. *Frontiers in Pharmacology*, **2021**, 12, 648262	5.6	
266	Endothelial nitric oxide synthase (NOS3) rs2070744 polymorphism and risk for multiple sclerosis. *Journal of Neural Transmission*, **2020**, 127, 1167-1175	4.3	1
265	Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2C9 and Nonsteroidal Anti-Inflammatory Drugs. *Clinical Pharmacology and Therapeutics*, **2020**, 108, 191-200	6.1	89
264	An update on the pharmacogenomics of NSAID metabolism and the risk of gastrointestinal bleeding. *Expert Opinion on Drug Metabolism and Toxicology*, **2020**, 16, 319-332	5.5	12
263	Sleep disorders in essential tremor: systematic review and meta-analysis. *Sleep*, **2020**, 43,	1.1	9
262	Photomutagenicity of chlorpromazine and its N-demethylated metabolites assessed by NGS. *Scientific Reports*, **2020**, 10, 6879	4.9	2
261	An Update on the Neurochemistry of Essential Tremor. *Current Medicinal Chemistry*, **2020**, 27, 1690-1710	4.3	5
260	Current and Future Neuropharmacological Options for the Treatment of Essential Tremor. *Current Neuropharmacology*, **2020**, 18, 518-537	7.6	9
259	The Relationship Between Parkinson Disease and Essential Tremor: Review of Clinical, Epidemiologic, Genetic, Neuroimaging and Neuropathological Data, and Data on the Presence of Cardinal Signs of Parkinsonism in Essential Tremor. *Tremor and Other Hyperkinetic Movements*, **2020**, 2, 02	2	11
258	Sleep disorders in tourette syndrome. *Sleep Medicine Reviews*, **2020**, 53, 101335	10.2	12
257	PharmVar GeneFocus: CYP2D6. *Clinical Pharmacology and Therapeutics*, **2020**, 107, 154-170	6.1	84
256	Association between endothelial nitric oxide synthase (NOS3) rs2070744 and the risk for migraine. *Pharmacogenomics Journal*, **2020**, 20, 426-432	3.5	6
255	Outcomes and Laboratory and Clinical Findings of Asthma and Allergic Patients Admitted With Covid-19 in a Spanish University Hospital. *Frontiers in Pharmacology*, **2020**, 11, 570721	5.6	2
254	Anti-Inflammatory Effects of Amantadine and Memantine: Possible Therapeutics for the Treatment of Covid-19?. *Journal of Personalized Medicine*, **2020**, 10,	3.6	16
253	Cerebrospinal and blood levels of amino acids as potential biomarkers for Parkinson's disease: review and meta-analysis. *European Journal of Neurology*, **2020**, 27, 2336-2347	6	11
252	Modulation of CYP2C9 activity and hydrogen peroxide production by cytochrome b. *Scientific Reports*, **2020**, 10, 15571	4.9	5

251	Pharmacogenetic Factors Affecting Asthma Treatment Response. Potential Implications for Drug Therapy. *Frontiers in Pharmacology*, **2019**, 10, 520	5.6	17
250	Association Study Among Candidate Genetic Polymorphisms and Chemotherapy-Related Severe Toxicity in Testicular Cancer Patients. *Frontiers in Pharmacology*, **2019**, 10, 206	5.6	5
249	Association between restless legs syndrome and other movement disorders. *Neurology*, **2019**, 92, 948-964	6.5	32
248	Neurochemical features of idiopathic restless legs syndrome. *Sleep Medicine Reviews*, **2019**, 45, 70-87	10.2	19
247	Next-Generation Sequencing of Genes Reveals an Increased Frequency of Non-synonymous Variants Among Patients With NSAID-Induced Liver Injury. *Frontiers in Genetics*, **2019**, 10, 134	4.5	7
246	Identification of Novel Biomarkers for Drug Hypersensitivity After Sequencing of the Promoter Area in 16 Genes of the Vitamin D Pathway and the High-Affinity IgE Receptor. *Frontiers in Genetics*, **2019**, 10, 582	4.5	6
245	The role of phase I and II genetic polymorphisms, smoking, alcohol and cancer family history, in the risk of developing testicular cancer. *Pharmacogenetics and Genomics*, **2019**, 29, 159-166	1.9	3
244	Alcohol consumption and risk for Parkinson's disease: a systematic review and meta-analysis. *Journal of Neurology*, **2019**, 266, 1821-1834	5.5	16
243	Association between the missense alcohol dehydrogenase rs1229984T variant with the risk for Parkinson's disease in women. *Journal of Neurology*, **2019**, 266, 346-352	5.5	9
242	Gamma-aminobutyric acid (GABA) receptors GABRA4, GABRE, and GABRQ gene polymorphisms and risk for migraine. *Journal of Neural Transmission*, **2018**, 125, 689-698	4.3	10
241	Gamma-aminobutyric acid (GABA) receptors genes polymorphisms and risk for restless legs syndrome. *Pharmacogenomics Journal*, **2018**, 18, 565-577	3.5	10
240	Genetics of restless legs syndrome: An update. *Sleep Medicine Reviews*, **2018**, 39, 108-121	10.2	45
239	Missense Gamma-Aminobutyric Acid Receptor Polymorphisms Are Associated with Reaction Time, Motor Time, and Ethanol Effects. *Frontiers in Cellular Neuroscience*, **2018**, 12, 10	6.1	4
238	Asthma and allergic rhinitis associate with the rs2229542 variant that induces a p.Lys90Glu mutation and compromises AKR1B1 protein levels. *Human Mutation*, **2018**, 39, 1081-1091	4.7	4
237	Hypersensitivity reactions to nonsteroidal anti-inflammatory drugs: an update on pharmacogenetics studies. *Pharmacogenomics*, **2018**, 19, 1069-1086	2.6	10
236	Human Arylamine N-Acetyltransferase Type 2: Phenotypic Correlation with Genotype-A Clinical Perspective **2018**, 69-89		5
235	NSAIDs-hypersensitivity often induces a blended reaction pattern involving multiple organs. *Scientific Reports*, **2018**, 8, 16710	4.9	22
234	The potential role of pharmacogenomics and biotransformation in hypersensitivity reactions to paracetamol. *Current Opinion in Allergy and Clinical Immunology*, **2018**, 18, 302-309	3.3	5

233	Delta-amino-levulinic acid dehydratase gene and essential tremor. *European Journal of Clinical Investigation*, **2017**, 47, 348-356	4.6	4
232	Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 genotype and use of ondansetron and tropisetron. *Clinical Pharmacology and Therapeutics*, **2017**, 102, 213-218	6.1	98
231	Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C19 and Voriconazole Therapy. *Clinical Pharmacology and Therapeutics*, **2017**, 102, 45-51	6.1	158
230	Immediate Reactions to More Than 1 NSAID Must Not Be Considered Cross-Hypersensitivity Unless Tolerance to ASA Is Verified. *Journal of Investigational Allergology and Clinical Immunology*, **2017**, 27, 32-39	2.3	16
229	Gamma-Aminobutyric Acid (Gaba) Receptors Rho (Gabrr) Gene Polymorphisms and Risk for Migraine. *Headache*, **2017**, 57, 1118-1135	4.2	11
228	Thr105Ile (rs11558538) polymorphism in the histamine-1-methyl-transferase (HNMT) gene and risk for restless legs syndrome. *Journal of Neural Transmission*, **2017**, 124, 285-291	4.3	9
227	Association Between the rs1229984 Polymorphism in the Alcohol Dehydrogenase 1B Gene and Risk for Restless Legs Syndrome. *Sleep*, **2017**, 40,	1.1	9
226	Molecular Interactions and Implications of Aldose Reductase Inhibition by PGA1 and Clinically Used Prostaglandins. *Molecular Pharmacology*, **2016**, 89, 42-52	4.3	14
225	7th drug hypersensitivity meeting: part one. *Clinical and Translational Allergy*, **2016**, 6,	5.2	2
224	Heme Oxygenase-1 and 2 Common Genetic Variants and Risk for Multiple Sclerosis. *Scientific Reports*, **2016**, 6, 20830	4.9	17
223	Pyrazolones metabolites are relevant for identifying selective anaphylaxis to metamizole. *Scientific Reports*, **2016**, 6, 23845	4.9	37
222	Genetics of Essential Tremor **2016**, 1-14		
221	Thr105Ile (rs11558538) polymorphism in the histamine N-methyltransferase (HNMT) gene and risk for Parkinson disease: A PRISMA-compliant systematic review and meta-analysis. *Medicine (United States)*, **2016**, 95, e4147	1.8	15
220	Allergic Reactions to Metamizole: Immediate and Delayed Responses. *International Archives of Allergy and Immunology*, **2016**, 169, 223-30	3.7	23
219	NAT2 polymorphisms and risk for Parkinson's disease: a systematic review and meta-analysis. *Expert Opinion on Drug Metabolism and Toxicology*, **2016**, 12, 937-46	5.5	2
218	Immediate hypersensitivity reactions to ibuprofen and other arylpropionic acid derivatives. *Allergy: European Journal of Allergy and Clinical Immunology*, **2016**, 71, 1048-56	9.3	14
217	An Update on the Role of Nitric Oxide in the Neurodegenerative Processes of Parkinson's Disease. *Current Medicinal Chemistry*, **2016**, 23, 2666-2679	4.3	37
216	New Advances in the Study of IgE Drug Recognition. *Current Pharmaceutical Design*, **2016**, 22, 6759-6772	3.3	5

215	The Genetics of Drug Hypersensitivity Reactions. *Journal of Investigational Allergology and Clinical Immunology*, **2016**, 26, 222-32, quiz next two pages	2.3	4
214	Asthma and Rhinitis Induced by Selective Immediate Reactions to Paracetamol and Non-steroidal Anti-inflammatory Drugs in Aspirin Tolerant Subjects. *Frontiers in Pharmacology*, **2016**, 7, 215	5.6	12
213	Detoxifying Enzymes at the Cross-Roads of Inflammation, Oxidative Stress, and Drug Hypersensitivity: Role of Glutathione Transferase P1-1 and Aldose Reductase. *Frontiers in Pharmacology*, **2016**, 7, 237	5.6	24
212	Pharmacogenomics of Prostaglandin and Leukotriene Receptors. *Frontiers in Pharmacology*, **2016**, 7, 316	5.6	22
211	FCERI and Histamine Metabolism Gene Variability in Selective Responders to NSAIDS. *Frontiers in Pharmacology*, **2016**, 7, 353	5.6	14
210	Copy number variation in ALOX5 and PTGER1 is associated with NSAIDs-induced urticaria and/or angioedema. *Pharmacogenetics and Genomics*, **2016**, 26, 280-7	1.9	13
209	GC Gene Polymorphism and Unbound Serum Retinol-Binding Protein 4 Are Related to the Risk of Insulin Resistance in Patients With Chronic Hepatitis C: A Prospective Cross-Sectional Study. *Medicine (United States)*, **2016**, 95, e3019	1.8	12
208	Pharmacogenetic allele nomenclature: International workgroup recommendations for test result reporting. *Clinical Pharmacology and Therapeutics*, **2016**, 99, 172-85	6.1	100
207	A Nonsynonymous FCER1B SNP is Associated with Risk of Developing Allergic Rhinitis and with IgE Levels. *Scientific Reports*, **2016**, 6, 19724	4.9	9
206	Advances in understanding genomic markers and pharmacogenetics of Parkinson's disease. *Expert Opinion on Drug Metabolism and Toxicology*, **2016**, 12, 433-48	5.5	23
205	A family study of DRD3 rs6280, SLC1A2 rs3794087 and MAPT rs1052553 variants in essential tremor. *Neurological Research*, **2016**, 38, 880-7	2.7	7
204	Neuronal nitric oxide synthase (nNOS, NOS1) rs693534 and rs7977109 variants and risk for restless legs syndrome. *Journal of Neural Transmission*, **2015**, 122, 819-23	4.3	20
203	Diamine oxidase rs10156191 and rs2052129 variants are associated with the risk for migraine. *Headache*, **2015**, 55, 276-86	4.2	36
202	Missense mutations in TENM4, a regulator of axon guidance and central myelination, cause essential tremor. *Human Molecular Genetics*, **2015**, 24, 5677-86	5.6	83
201	TREM2 R47H variant and risk of essential tremor: a cross-sectional international multicenter study. *Parkinsonism and Related Disorders*, **2015**, 21, 306-9	3.6	26
200	The potential of LINGO-1 as a therapeutic target for essential tremor. *Expert Opinion on Therapeutic Targets*, **2015**, 19, 1139-48	6.4	9
199	The GSTP1 gene variant rs1695 is not associated with an increased risk of multiple sclerosis. *Cellular and Molecular Immunology*, **2015**, 12, 777-9	15.4	4
198	Genetic determinants of metamizole metabolism modify the risk of developing anaphylaxis. *Pharmacogenetics and Genomics*, **2015**, 25, 462-4	1.9	20

197	Neuronal Nitric Oxide Synthase (nNOS, NOS1) rs693534 and rs7977109 Variants and Risk for Migraine. *Headache*, **2015**, 55, 1209-17	4.2	14
196	Association Between Vitamin D Receptor rs731236 (Taq1) Polymorphism and Risk for Restless Legs Syndrome in the Spanish Caucasian Population. *Medicine (United States)*, **2015**, 94, e2125	1.8	18
195	Drug metabolism and hypersensitivity reactions to drugs. *Current Opinion in Allergy and Clinical Immunology*, **2015**, 15, 277-84	3.3	7
194	Editorial on Cerebral endothelial and glial cells are more than bricks in the Great Wall of the brain: insights into the way the blood-brain barrier actually works (celebrating the centenary of Goldman's experiments). *Frontiers in Cellular Neuroscience*, **2015**, 9, 128	6.1	1
193	Pharmacogenomics of cyclooxygenases. *Pharmacogenomics*, **2015**, 16, 501-22	2.6	31
192	Heme Oxygenase 1 and 2 Common Genetic Variants and Risk for Essential Tremor. *Medicine (United States)*, **2015**, 94, e968	1.8	17
191	Heme Oxygenase-1 and 2 Common Genetic Variants and Risk for Restless Legs Syndrome. *Medicine (United States)*, **2015**, 94, e1448	1.8	28
190	Neurochemistry of Idiopathic Restless Legs Syndrome. *European Neurological Review*, **2015**, 10, 35	0.5	7
189	Treatment Options for Idiopathic Restless Legs Syndrome. *European Neurological Review*, **2015**, 10, 45	0.5	2
188	SLC1A2 rs3794087 variant and risk for essential tremor: a systematic review and meta-analysis. *Pharmacogenetics and Genomics*, **2015**, 25, 564-8	1.9	10
187	SLC1A2 rs3794087 variant and risk for migraine. *Journal of the Neurological Sciences*, **2014**, 338, 92-5	3.2	11
186	Evaluation of immediate allergic reactions to dipyrone using dipyrone metabolites in basophil activation test. *Clinical and Translational Allergy*, **2014**, 4, P33	5.2	78
185	NQO1 gene rs1800566 variant is not associated with risk for multiple sclerosis. *BMC Neurology*, **2014**, 14, 87	3.1	8
184	Gender and functional CYP2C and NAT2 polymorphisms determine the metabolic profile of metamizole. *Biochemical Pharmacology*, **2014**, 92, 457-66	6	23
183	Pharmacogenomics testing for type B adverse drug reactions to anti-infective drugs: the example of hypersensitivity to abacavir. *Recent Patents on Anti-infective Drug Discovery*, **2014**, 9, 151	1.6	1
182	Variants of CEP68 gene are associated with acute urticaria/angioedema induced by multiple non-steroidal anti-inflammatory drugs. *PLoS ONE*, **2014**, 9, e90966	3.7	17
181	An association study between Heme oxygenase-1 genetic variants and Parkinson's disease. *Frontiers in Cellular Neuroscience*, **2014**, 8, 298	6.1	29
180	Drug and xenobiotic biotransformation in the blood-brain barrier: a neglected issue. *Frontiers in Cellular Neuroscience*, **2014**, 8, 335	6.1	28

179	Incorporation of pharmacogenomics into routine clinical practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline development process. *Current Drug Metabolism*, **2014**, 15, 209-17	3.5	265
178	Clinical practice guidelines for translating pharmacogenomic knowledge to bedside. Focus on anticancer drugs. *Frontiers in Pharmacology*, **2014**, 5, 188	5.6	2
177	COMT gene and risk for Parkinson's disease: a systematic review and meta-analysis. *Pharmacogenetics and Genomics*, **2014**, 24, 331-9	1.9	22
176	Cerebrospinal fluid biochemical studies in patients with Parkinson's disease: toward a potential search for biomarkers for this disease. *Frontiers in Cellular Neuroscience*, **2014**, 8, 369	6.1	50
175	PITX3 and risk for Parkinson's disease: a systematic review and meta-analysis. *European Neurology*, **2014**, 71, 49-56	2.1	13
174	The solute carrier family 1 (glial high affinity glutamate transporter), member 2 gene, SLC1A2, rs3794087 variant and assessment risk for restless legs syndrome. *Sleep Medicine*, **2014**, 15, 266-8	4.6	15
173	Genomic and pharmacogenomic biomarkers of Parkinson's disease. *Current Drug Metabolism*, **2014**, 15, 129-81	3.5	32
172	Gene variants and haplotypes modifying transcription factor binding sites in the human cyclooxygenase 1 and 2 (PTGS1 and PTGS2) genes. *Current Drug Metabolism*, **2014**, 15, 182-95	3.5	19
171	Perception of the usefulness of drug/gene pairs and barriers for pharmacogenomics in Latin America. *Current Drug Metabolism*, **2014**, 15, 202-8	3.5	23
170	Importance of CYP2D6 genotype/activity testing and applications **2014**, 118-133		1
169	LINGO1 rs9652490 and rs11856808 polymorphisms are not associated with risk for multiple sclerosis. *BMC Neurology*, **2013**, 13, 34	3.1	7
168	MAPT1 gene rs1052553 variant is unrelated with the risk for restless legs syndrome. *Journal of Neural Transmission*, **2013**, 120, 463-7	4.3	14
167	Metabolic considerations of drugs in the treatment of allergic diseases. *Expert Opinion on Drug Metabolism and Toxicology*, **2013**, 9, 1437-52	5.5	4
166	Dopamine receptor D3 (DRD3) gene rs6280 variant and risk for restless legs syndrome. *Sleep Medicine*, **2013**, 14, 382-4	4.6	13
165	Fused in Sarcoma (FUS) gene mutations are not a frequent cause of essential tremor in Europeans. *Neurobiology of Aging*, **2013**, 34, 2441.e9-2441.e11	5.6	21
164	MAPT gene rs1052553 variant is not associated with the risk for multiple sclerosis. *Human Immunology*, **2013**, 74, 1705-8	2.3	3
163	Anti-Parkinson's disease drugs and pharmacogenetic considerations. *Expert Opinion on Drug Metabolism and Toxicology*, **2013**, 9, 859-74	5.5	40
162	Update on genetics of essential tremor. *Acta Neurologica Scandinavica*, **2013**, 128, 359-71	3.8	38

161	Genome-wide association study raised biomarker SLC1A2 rs3794087 and essential tremor: is it too early to say?. *Pharmacogenomics*, **2013**, 14, 1679-80	2.6	5
160	Variability in histamine receptor genes HRH1, HRH2 and HRH4 in patients with hypersensitivity to NSAIDs. *Pharmacogenomics*, **2013**, 14, 1871-8	2.6	17
159	No association of the SLC1A2 rs3794087 allele with risk for essential tremor in the Spanish population. *Pharmacogenetics and Genomics*, **2013**, 23, 587-90	1.9	18
158	Clarifying haplotype ambiguity of NAT2 in multi-national cohorts. *Frontiers in Bioscience - Scholar*, **2013**, 5, 672-84	2.4	9
157	Vitamin D3 receptor (VDR) gene rs2228570 (Fok1) and rs731236 (Taq1) variants are not associated with the risk for multiple sclerosis: results of a new study and a meta-analysis. *PLoS ONE*, **2013**, 8, e65487	3.7	50
156	Functional polymorphisms of xenobiotics metabolizing enzymes-a research topic. *Frontiers in Genetics*, **2013**, 4, 79	4.5	1
155	Influence of vitamin D-related gene polymorphisms (CYP27B and VDR) on the response to interferon/ribavirin therapy in chronic hepatitis C. *PLoS ONE*, **2013**, 8, e74764	3.7	32
154	Latest Perspectives in Genetic Risk Factors for Restless Legs Syndrome. *European Neurological Review*, **2013**, 8, 90	0.5	7
153	Hereditary Coproporphyria Associated with the Q306X Mutation in the Coproporphyrin Oxidase Gene Presenting with Acute Ataxia. *Tremor and Other Hyperkinetic Movements*, **2013**, 3,	2	1
152	Modulation of GSTP1-1 oligomerization by electrophilic inflammatory mediators and reactive drugs. *Inflammation and Allergy: Drug Targets*, **2013**, 12, 162-71		10
151	FUS: a putative biomarker for essential tremor raised by whole-exome sequencing analyses. *Pharmacogenomics*, **2013**, 14, 1680-1	2.6	4
150	Genetic biomarkers of essential tremor: time to think outside of the box. *Pharmacogenomics*, **2013**, 14, 1681-2	2.6	2
149	LINGO1 rs9652490 and rs11856808 are not associated with the risk of Parkinson's disease: results of a meta-analysis. *Parkinsonism and Related Disorders*, **2012**, 18, 657-9	3.6	7
148	Genetic variants of the arachidonic acid pathway in non-steroidal anti-inflammatory drug-induced acute urticaria. *Clinical and Experimental Allergy*, **2012**, 42, 1772-81	4.1	43
147	Polymorphism of the TLR4 gene reduces the risk of hepatitis C virus-induced hepatocellular carcinoma. *Oncology*, **2012**, 82, 35-40	3.6	44
146	LINGO1 and risk for essential tremor: results of a meta-analysis of rs9652490 and rs11856808. *Journal of the Neurological Sciences*, **2012**, 317, 52-7	3.2	35
145	Detection of genomic variations in BRCA1 and BRCA2 genes by long-range PCR and next-generation sequencing. *Journal of Molecular Diagnostics*, **2012**, 14, 286-93	5.1	43
144	Relation of IL28B gene polymorphism with biochemical and histological features in hepatitis C virus-induced liver disease. *PLoS ONE*, **2012**, 7, e37998	3.7	42

143	H1-MAPT and the risk for familial essential tremor. *PLoS ONE*, **2012**, 7, e41581	3.7	15
142	The differential effect of NAT2 variant alleles permits refinement in phenotype inference and identifies a very slow acetylation genotype. *PLoS ONE*, **2012**, 7, e44629	3.7	34
141	Trends in qualifying biomarkers in drug safety. Consensus of the 2011 meeting of the spanish society of clinical pharmacology. *Frontiers in Pharmacology*, **2012**, 3, 2	5.6	10
140	Frequencies of 23 functionally significant variant alleles related with metabolism of antineoplastic drugs in the chilean population: comparison with caucasian and asian populations. *Frontiers in Genetics*, **2012**, 3, 229	4.5	49
139	Toward a clinical practice guide in pharmacogenomics testing for functional polymorphisms of drug-metabolizing enzymes. Gene/drug pairs and barriers perceived in Spain. *Frontiers in Genetics*, **2012**, 3, 273	4.5	16
138	Analysis of the Functional Polymorphism in the Cytochrome P450 CYP2C8 Gene rs11572080 with Regard to Colorectal Cancer Risk. *Frontiers in Genetics*, **2012**, 3, 278	4.5	7
137	Predicting response to therapy in chronic hepatitis C: an approach combining interleukin-28B gene polymorphisms and clinical data. *Journal of Gastroenterology and Hepatology (Australia)*, **2012**, 27, 279-85	4	21
136	High-resolution melting analysis of the common c.1905+1G>A mutation causing dihydropyrimidine dehydrogenase deficiency and lethal 5-fluorouracil toxicity. *Frontiers in Genetics*, **2012**, 3, 312	4.5	5
135	The diamine oxidase gene is associated with hypersensitivity response to non-steroidal anti-inflammatory drugs. *PLoS ONE*, **2012**, 7, e47571	3.7	39
134	Arylamine N-acetyltransferase 2 genotypes in a Mexican population. *Genetics and Molecular Research*, **2012**, 11, 1082-92	1.2	10
133	The relationship between Parkinson's disease and essential tremor: review of clinical, epidemiologic, genetic, neuroimaging and neuropathological data, and data on the presence of cardinal signs of parkinsonism in essential tremor. *Tremor and Other Hyperkinetic Movements*, **2012**, 2,	2	10
132	Influence of age and gender in motor performance in healthy subjects. *Journal of the Neurological Sciences*, **2011**, 302, 72-80	3.2	41
131	N-acetyltransferase 2 polymorphisms and risk of anti-tuberculosis drug-induced hepatotoxicity in Caucasians. *International Journal of Tuberculosis and Lung Disease*, **2011**, 15, 1403-8	2.1	37
130	Determinación del polimorfismo de CYP2C9*2 y su relación con la farmacocinética de acenocumarol en voluntarios sanos. *Revista Chilena De Cardiología*, **2011**, 30, 218-224	0.3	2
129	Acetylator status and N-acetyltransferase 2 gene polymorphisms; phenotype-genotype correlation with the sulfamethazine test. *Pharmacogenetics and Genomics*, **2011**, 21, 894-901	1.9	11
128	Gamma-aminobutyric acid GABRA4, GABRE, and GABRQ receptor polymorphisms and risk for essential tremor. *Pharmacogenetics and Genomics*, **2011**, 21, 436-9	1.9	25
127	A polymorphism located at an ATG transcription start site of the heme oxygenase-2 gene is associated with classical Parkinson's disease. *Pharmacogenetics and Genomics*, **2011**, 21, 565-71	1.9	12
126	Cytochrome P450 CYP2B6 genotypes and haplotypes in a Colombian population: identification of novel variant CYP2B6 alleles. *Pharmacogenetics and Genomics*, **2011**, 21, 773-8	1.9	9

125	Characteristics of subjects experiencing hypersensitivity to non-steroidal anti-inflammatory drugs: patterns of response. *Clinical and Experimental Allergy*, **2011**, 41, 86-95	4.1	144
124	Lack of association of LINGO1 rs9652490 and rs11856808 SNPs with familial essential tremor. *European Journal of Neurology*, **2011**, 18, 1085-9	6	27
123	Gamma-aminobutyric acid (GABA) receptor rho (GABRR) polymorphisms and risk for essential tremor. *Journal of Neurology*, **2011**, 258, 203-11	5.5	25
122	Clinical pharmacogenomic testing of KRAS, BRAF and EGFR mutations by high resolution melting analysis and ultra-deep pyrosequencing. *BMC Cancer*, **2011**, 11, 406	4.8	75
121	LINGO1 gene analysis in Parkinson's disease phenotypes. *Movement Disorders*, **2011**, 26, 722-7	7	15
120	Assessment of nonsteroidal anti-inflammatory drug-induced hepatotoxicity. *Expert Opinion on Drug Metabolism and Toxicology*, **2011**, 7, 817-28	5.5	38
119	Variability of the L-Histidine decarboxylase gene in allergic rhinitis. *Allergy: European Journal of Allergy and Clinical Immunology*, **2010**, 65, 1576-84	9.3	23
118	CYP2W1 variant alleles in Caucasians and association of the CYP2W1 G541A (Ala181Thr) polymorphism with increased colorectal cancer risk. *Pharmacogenomics*, **2010**, 11, 919-25	2.6	9
117	Loss-of-function mutations in HPSE2 cause the autosomal recessive urofacial syndrome. *American Journal of Human Genetics*, **2010**, 86, 957-62	11	63
116	Paraoxonase 1 (PON1) polymorphisms and risk for migraine. *Journal of Neurology*, **2010**, 257, 1482-5	5.5	14
115	Paraoxonase 1 polymorphisms are not related with the risk for multiple sclerosis. *NeuroMolecular Medicine*, **2010**, 12, 217-23	4.6	16
114	Two common nonsynonymous paraoxonase 1 (PON1) gene polymorphisms and brain astrocytoma and meningioma. *BMC Neurology*, **2010**, 10, 71	3.1	22
113	Oxidative stress in skin fibroblasts cultures from patients with Parkinson's disease. *BMC Neurology*, **2010**, 10, 95	3.1	33
112	Variability in ethanol biodisposition in whites is modulated by polymorphisms in the ADH1B and ADH1C genes. *Hepatology*, **2010**, 51, 491-500	11.2	26
111	Mitochondrial superoxide dismutase and glutathione peroxidase in idiosyncratic drug-induced liver injury. *Hepatology*, **2010**, 52, 303-12	11.2	85
110	Histamine-N-methyl transferase polymorphism and risk for multiple sclerosis. *European Journal of Neurology*, **2010**, 17, 335-8	6	12
109	Impairment of rapid repetitive finger movements and visual reaction time in patients with essential tremor. *European Journal of Neurology*, **2010**, 17, 152-9	6	48
108	Paraoxonase 1 (PON1) polymorphisms and risk for essential tremor. *European Journal of Neurology*, **2010**, 17, 879-81	6	8

107	Dopamine receptor 3 (DRD3) polymorphism and risk for migraine. *European Journal of Neurology*, **2010**, 17, 1220-1223	6	11
106	Alcohol dehydrogenase 2 genotype and risk for migraine. *Headache*, **2010**, 50, 85-91	4.2	22
105	Pharmacogenomics in aspirin intolerance. *Current Drug Metabolism*, **2009**, 10, 998-1008	3.5	46
104	Polymorphic drug metabolism in anaesthesia. *Current Drug Metabolism*, **2009**, 10, 236-46	3.5	67
103	Glutathione S-transferase M1 and T1 null genotypes increase susceptibility to drug-induced liver injury. *Hepatology*, **2009**, 49, 1777; author reply 1777-9	11.2	0
102	Reply:. *Hepatology*, **2009**, 49, 1777-1779	11.2	
101	Dopamine receptor D3 (DRD3) genotype and allelic variants and risk for essential tremor. *Movement Disorders*, **2009**, 24, 1910-5	7	22
100	Motor performance in patients with restless legs syndrome. *Movement Disorders*, **2009**, 24, 1656-61	7	6
99	Histamine pharmacogenomics. *Pharmacogenomics*, **2009**, 10, 867-83	2.6	60
98	Genetically based impairment in CYP2C8- and CYP2C9-dependent NSAID metabolism as a risk factor for gastrointestinal bleeding: is a combination of pharmacogenomics and metabolomics required to improve personalized medicine?. *Expert Opinion on Drug Metabolism and Toxicology*, **2009**, 5, 607-20	5.5	80
97	Analysis of a non-synonymous single nucleotide polymorphism of the human diamine oxidase gene (ref. SNP ID: rs1049793) in patients with Crohn's disease. *Scandinavian Journal of Gastroenterology*, **2009**, 44, 1207-12	2.4	2
96	Pharmacogenomics in drug induced liver injury. *Current Drug Metabolism*, **2009**, 10, 956-70	3.5	61
95	Hypersensitivity reactions to non-steroidal anti-inflammatory drugs. *Current Drug Metabolism*, **2009** , 10, 971-80	3.5	48
94	A genome-wide association study identifies colorectal cancer susceptibility loci on chromosomes 10p14 and 8q23.3. *Nature Genetics*, **2008**, 40, 623-30	36.3	463
93	Histamine-N-methyl transferase polymorphism and risk for migraine. *Headache*, **2008**, 48, 1343-8	4.2	19
92	Glutathione-S-transferase P1 polymorphism and risk for essential tremor. *European Journal of Neurology*, **2008**, 15, 234-8	6	16
91	Refinement of the basis and impact of common 11q23.1 variation to the risk of developing colorectal cancer. *Human Molecular Genetics*, **2008**, 17, 3720-7	5.6	57
90	Unraveling ambiguous NAT2 genotyping data. *Clinical Chemistry*, **2008**, 54, 1390-4	5.5	58

89	Polymorphisms of human N-acetyltransferases and cancer risk. *Current Drug Metabolism*, **2008**, 9, 520-31	3.5	113
88	Interaction of CYP2C8 and CYP2C9 genotypes modifies the risk for nonsteroidal anti-inflammatory drugs-related acute gastrointestinal bleeding. *Pharmacogenetics and Genomics*, **2008**, 18, 37-43	1.9	57
87	Nonsynonymous polymorphisms of histamine-metabolising enzymes in patients with Parkinson's disease. *NeuroMolecular Medicine*, **2008**, 10, 10-6	4.6	27
86	The nonsynonymous Thr105Ile polymorphism of the histamine N-methyltransferase is associated to the risk of developing essential tremor. *NeuroMolecular Medicine*, **2008**, 10, 356-61	4.6	22
85	Genetic variability of histamine receptors in patients with Parkinson's disease. *BMC Medical Genetics*, **2008**, 9, 15	2.1	22
84	Glutathione S-transferase m1 and t1 null genotypes increase susceptibility to idiosyncratic drug-induced liver injury. *Hepatology*, **2008**, 48, 588-96	11.2	162
83	Response to the Letter to the Editor regarding "Improved analytical sensitivity reveals the occurrence of gender-related variability in diamine oxidase enzyme activity in healthy individuals" *Clinical Biochemistry*, **2008**, 41, 1260-1261	3.5	
82	Glutathione S-transferase GSTT1 and GSTM1 allozymes: beyond null alleles. *Pharmacogenomics*, **2008**, 9, 359-63	2.6	19
81	Cytochrome P450 CYP2C9 polymorphism and NSAID-related acute gastrointestinal bleeding. *Gastroenterology*, **2007**, 133, 2071-2; author reply 2072-3	13.3	8
80	Improved analytical sensitivity reveals the occurrence of gender-related variability in diamine oxidase enzyme activity in healthy individuals. *Clinical Biochemistry*, **2007**, 40, 1339-41	3.5	24
79	Polymorphisms of histamine-metabolizing enzymes and clinical manifestations of asthma and allergic rhinitis. *Clinical and Experimental Allergy*, **2007**, 37, 1175-82	4.1	43
78	Genetic variability in CYP3A4 and CYP3A5 in primary liver, gastric and colorectal cancer patients. *BMC Cancer*, **2007**, 7, 118	4.8	13
77	Changes at the CYP2C locus and disruption of CYP2C8/9 linkage disequilibrium in patients with essential tremor. *NeuroMolecular Medicine*, **2007**, 9, 195-204	4.6	16
76	GSTT1 and GSTM1 null genotypes may facilitate hepatitis C virus infection becoming chronic. *Journal of Infectious Diseases*, **2007**, 195, 1320-3	7	18
75	Glutathione S-transferases pi 1, alpha 1 and M3 genetic polymorphisms and the risk of hepatocellular carcinoma in humans. *Pharmacogenomics*, **2007**, 8, 895-9	2.6	11
74	Effect of common NAT2 variant alleles in the acetylation of the major clonazepam metabolite, 7-aminoclonazepam. *Drug Metabolism Letters*, **2007**, 1, 3-5	2.1	18
73	Genetic variability of human diamine oxidase: occurrence of three nonsynonymous polymorphisms and study of their effect on serum enzyme activity. *Pharmacogenetics and Genomics*, **2007**, 17, 687-93	1.9	29
72	Effect of neurotransmitters on NADPH-cytochrome P450 reductase in vitro activity. *Drug Metabolism Letters*, **2007**, 1, 172-5	2.1	2

71	Changes at the CYP2C locus and disruption of CYP2C8/9 linkage disequilibrium in patients with essential tremor. *NeuroMolecular Medicine*, **2007**, 9, 195-204	4.6	
70	Alcohol dehydrogenase 2 genotype and allelic variants are not associated with the risk for essential tremor. *Clinical Neuropharmacology*, **2007**, 30, 196-200	1.4	19
69	CYP2C19 polymorphism and risk for essential tremor. *European Neurology*, **2006**, 56, 119-23	2.1	28
68	Glutathione S-transferases mu 1, theta 1, pi 1, alpha 1 and mu 3 genetic polymorphisms and the risk of colorectal and gastric cancers in humans. *Pharmacogenomics*, **2006**, 7, 711-8	2.6	72
67	Acquired resistance to the anticancer drug paclitaxel is associated with induction of cytochrome P450 2C8. *Pharmacogenomics*, **2006**, 7, 575-85	2.6	40
66	Interethnic and intraethnic variability of CYP2C8 and CYP2C9 polymorphisms in healthy individuals. *Molecular Diagnosis and Therapy*, **2006**, 10, 29-40	4.5	144
65	Glutathione S-transferase M1 and T1 genetic polymorphisms are not related to the risk of hepatocellular carcinoma: a study in the Spanish population. *European Journal of Cancer*, **2006**, 42, 73-7	7.5	21
64	Increased frequency of rapid acetylator genotypes in patients with brain astrocytoma and meningioma. *Acta Neurologica Scandinavica*, **2006**, 113, 322-6	3.8	8
63	Severity of ulcerative colitis is associated with a polymorphism at diamine oxidase gene but not at histamine N-methyltransferase gene. *World Journal of Gastroenterology*, **2006**, 12, 615-20	5.6	31
62	Polymorphisms of the glutathione S-transferases mu-1 (GSTM1) and theta-1 (GSTT1) and the risk of advanced alcoholic liver disease. *Scandinavian Journal of Gastroenterology*, **2005**, 40, 348-53	2.4	50
61	Polymorphisms in the transforming growth factor-beta gene (TGF-beta) and the risk of advanced alcoholic liver disease. *Liver International*, **2005**, 25, 935-9	7.9	19
60	The effect of the cytochrome P450 CYP2C8 polymorphism on the disposition of (R)-ibuprofen enantiomer in healthy subjects. *British Journal of Clinical Pharmacology*, **2005**, 59, 62-9	3.8	99
59	Cytochrome P450 Gene Polymorphisms and Variability in Response to NSAIDs. *Clinical Research and Regulatory Affairs*, **2005**, 22, 57-81		16
58	Identification of subtypes of CYP2D gene rearrangements among carriers of CYP2D6 gene deletion and duplication. *Clinical Chemistry*, **2005**, 51, 939-43	5.5	30
57	Cytochrome P450 gene polymorphism and cancer. *Current Drug Metabolism*, **2004**, 5, 211-24	3.5	233
56	Genetic predisposition to acute gastrointestinal bleeding after NSAIDs use. *British Journal of Pharmacology*, **2004**, 141, 205-8	8.6	93
55	Interindividual variability in ibuprofen pharmacokinetics is related to interaction of cytochrome P450 2C8 and 2C9 amino acid polymorphisms. *Clinical Pharmacology and Therapeutics*, **2004**, 76, 119-27	6.1	135
54	Leflunomide-induced acute hepatitis. *Digestive and Liver Disease*, **2004**, 36, 82-4	3.3	49

53	High resolution mapping and mutation analyses of candidate genes in the urofacial syndrome (UFS) critical region. *American Journal of Medical Genetics Part A*, **2003**, 119A, 9-14		19
52	N-acetyltransferase 2 single-nucleotide polymorphisms and risk of gastric carcinoma. *European Journal of Clinical Pharmacology*, **2002**, 58, 115-8	2.8	17
51	Single nucleotide polymorphisms and microsatellite alleles of tumor necrosis factor alpha and interleukin-10 genes and the risk of advanced chronic alcoholic liver disease. *Liver*, **2002**, 22, 245-51		29
50	Expression of paclitaxel-inactivating CYP3A activity in human colorectal cancer: implications for drug therapy. *British Journal of Cancer*, **2002**, 87, 681-6	8.7	48
49	CYP3A4 variant alleles in white individuals with low CYP3A4 enzyme activity. *Clinical Pharmacology and Therapeutics*, **2002**, 71, 196-204	6.1	104
48	N-acetyltransferase 2 polymorphism is not related to the risk of advanced alcoholic liver disease. *Scandinavian Journal of Gastroenterology*, **2002**, 37, 99-103	2.4	14
47	Influence of cytochrome P450 CYP2C9 genotypes in lung cancer risk. *Cancer Letters*, **2002**, 180, 41-6	9.9	21
46	High frequency of mutations related to impaired CYP2C9 metabolism in a Caucasian population. *European Journal of Clinical Pharmacology*, **2001**, 57, 47-9	2.8	71
45	Association of CYP2C9 genotypes leading to high enzyme activity and colorectal cancer risk. *Carcinogenesis*, **2001**, 22, 1323-6	4.6	44
44	Functionally active duplications of the CYP2D6 gene are more prevalent among larynx and lung cancer patients. *Oncology*, **2001**, 61, 59-63	3.6	35
43	Inhibition of cytochrome P450 2C9 activity in vitro by 5-hydroxytryptamine and adrenaline. *Pharmacogenetics and Genomics*, **2001**, 11, 29-37		22
42	Modulation of midazolam 1-hydroxylation activity in vitro by neurotransmitters and precursors. *European Journal of Clinical Pharmacology*, **2000**, 56, 145-51	2.8	18
41	N-acetyltransferase 2 (NAT2) genotype and colorectal carcinoma: risk variability according to tumour site?. *Scandinavian Journal of Gastroenterology*, **2000**, 35, 1087-91	2.4	15
40	Comparative in vitro and in vivo inhibition of cytochrome P450 CYP1A2, CYP2D6, and CYP3A by H2-receptor antagonists. *Clinical Pharmacology and Therapeutics*, **1999**, 65, 369-76	6.1	92
39	Identification and characterisation of novel polymorphisms in the CYP2A locus: implications for nicotine metabolism. *FEBS Letters*, **1999**, 460, 321-7	3.8	135
38	Pharmacokinetic interaction of fluvoxamine and thioridazine in schizophrenic patients. *Journal of Clinical Psychopharmacology*, **1999**, 19, 494-9	1.7	49
37	Influence of genetic admixture on polymorphisms of drug-metabolizing enzymes: analyses of mutations on NAT2 and C gamma P2E1 genes in a mixed Hispanic population. *Clinical Pharmacology and Therapeutics*, **1998**, 63, 623-8	6.1	27
36	Expression in human prostate of drug- and carcinogen-metabolizing enzymes: association with prostate cancer risk. *British Journal of Cancer*, **1998**, 78, 1361-7	8.7	45

35	Analysis of midazolam and metabolites in plasma by high-performance liquid chromatography: probe of CYP3A. *Therapeutic Drug Monitoring*, **1998**, 20, 319-24	3.2	58
34	CYP2D6 polymorphism is not associated with essential tremor. *European Neurology*, **1997**, 38, 99-104	2.1	19
33	CYP2D6, NAT2 and CYP2E1 genetic polymorphisms in nonagenarians. *Age and Ageing*, **1997**, 26, 147-51	3	39
32	Tryptamine: a possible endogenous substrate for CYP2D6. *Pharmacogenetics and Genomics*, **1997**, 7, 85-93		43
31	CYP2A6 gene polymorphism and risk of liver cancer and cirrhosis. *Pharmacogenetics and Genomics*, **1997**, 7, 247-50		29
30	Molecular heterogeneity at the CYP2D gene locus in Nicaraguans: impact of gene-flow from Europe. *Pharmacogenetics and Genomics*, **1997**, 7, 337-40		20
29	Rsa I polymorphism at the cytochrome P4502E1 locus is not related to the risk of alcohol-related severe liver disease. *Liver*, **1996**, 16, 380-3		19
28	Changes induced by ovariectomy on the acute effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in a model of rat poor metabolizer of debrisoquine. *Parkinsonism and Related Disorders*, **1996**, 2, 7-12	3.6	
27	CYP2D6 genotypes in Spanish women with breast cancer. *Cancer Letters*, **1996**, 99, 23-8	9.9	22
26	Identification and prevalence study of 17 allelic variants of the human NAT2 gene in a white population. *Pharmacogenetics and Genomics*, **1996**, 6, 423-428		66
25	Genetic analysis of the NAT2 and CYP2D6 polymorphisms in white patients with non-insulin-dependent diabetes mellitus. *Pharmacogenetics and Genomics*, **1996**, 6, 465-72		15
24	Increased risk for hepatocellular carcinoma in NAT2-slow acetylators and CYP2D6-rapid metabolizers. *Pharmacogenetics and Genomics*, **1996**, 6, 501-12		54
23	RsaI polymorphism at the cytochrome P4502E1 locus and risk of hepatocellular carcinoma. *Gut*, **1996**, 39, 330-3	19.2	44
22	Determination of aminopyrine and dipyrone metabolites in urine. *Therapeutic Drug Monitoring*, **1996**, 18, 104-7	3.2	7
21	Frequency of CYP2D6 allelic variants in multiple sclerosis. *Acta Neurologica Scandinavica*, **1995**, 92, 464-7	3.8	5
20	Metabolism of aminopyrine and derivatives in man: in vivo study of monomorphic and polymorphic metabolic pathways. *Xenobiotica*, **1995**, 25, 417-27	2	34
19	CYP2D6 genes and risk of liver cancer. *Lancet, The*, **1995**, 345, 830-1	40	51
18	Aminopyrine Metabolism in Man. *Therapeutic Drug Monitoring*, **1995**, 17, 1-5	3.2	9

17	Genetic analysis of the arylamine N-acetyltransferase polymorphism in breast cancer patients. *Oncology*, **1995**, 52, 7-11	3.6	36
16	Prevalence of CYP2D6 gene duplication and its repercussion on the oxidative phenotype in a white population. *Clinical Pharmacology and Therapeutics*, **1995**, 57, 265-9	6.1	154
15	Association between the oxidative polymorphism and early onset of Parkinson's disease. *Clinical Pharmacology and Therapeutics*, **1995**, 57, 291-8	6.1	59
14	Possible implications of doxycycline-rifampin interaction for treatment of brucellosis. *Antimicrobial Agents and Chemotherapy*, **1994**, 38, 2798-802	5.9	64
13	Debrisoquin oxidation genotype and susceptibility to lung cancer. *Clinical Pharmacology and Therapeutics*, **1994**, 55, 10-4	6.1	45
12	Genetic basis for differences in debrisoquin polymorphism between a Spanish and other white populations. *Clinical Pharmacology and Therapeutics*, **1994**, 55, 412-7	6.1	43
11	Molecular analysis of the arylamine N-acetyltransferase polymorphism in a Spanish population. *Clinical Pharmacology and Therapeutics*, **1994**, 56, 202-9	6.1	28
10	Determination of aminopyrine, dipyrone and its metabolites in urine by high-performance liquid chromatography. *Therapeutic Drug Monitoring*, **1994**, 16, 316-22	3.2	25
9	Debrisoquine polymorphism: mechanism for very rapid oxidative phenotype. *Lancet, The*, **1993**, 341, 689	40	
8	Caffeine demethylase activity in human and Dark Agouti rat liver microsomes. Comparison with aminopyrine N-demethylase activity. *Drug Metabolism and Disposition*, **1992**, 20, 343-9	4	6
7	Acute effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in a model of rat designated a poor metabolizer of debrisoquine. *Journal of Neurochemistry*, **1991**, 57, 81-7	6	38
6	Sex and age-related differences in aminopyrine N-demethylase activity in DA- and Wistar-strain rat liver microsomes. Effect of ovariectomy. *Xenobiotica*, **1991**, 21, 755-62	2	6
5	Particulate diadenosine 5',5"'-P1,P3-triphosphate hydrolases in rat brain: two specific dinucleoside triphosphatases and two phosphodiesterase I-like hydrolases. *Biochimica Et Biophysica Acta - General Subjects*, **1991**, 1073, 402-9	4	8
4	Dinucleoside tetraphosphatase from human blood cells. Purification and characterization as a high specific activity enzyme recognized by an anti-rat tetraphosphatase antibody. *FEBS Letters*, **1991**, 287, 85-8	3.8	5
3	Aminopyrine N-demethylase activity in human liver microsomes. *Clinical Pharmacology and Therapeutics*, **1990**, 48, 490-5	6.1	20
2	Purification to homogeneity of rat liver dinucleoside tetraphosphatase by affinity elution with adenosine 5'-tetraphosphate. *Journal of Proteomics*, **1990**, 21, 25-33		8
1	Genetics of Restless Legs Syndrome1-23		